GLP-1 and GIP in Weight Management

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 and GIP are incretin hormones produced in your intestines that regulate blood glucose, appetite signaling, and satiety. Together, they account for 50-70% of the total insulin secretion response after eating, making them central to metabolic health and weight regulation.

Understanding these hormones goes beyond mechanism—it includes recognizing your individual genetic predispositions and metabolic profile. PlexusDx emphasizes precision wellness by connecting hormone biology to your unique genetic and biomarker context, enabling more informed conversations with your healthcare provider about treatment options.

GLP-1: The Appetite and Blood Sugar Regulator

Glucagon-like peptide-1 (GLP-1) is released from intestinal L-cells in response to glucose and nutrients. It stimulates insulin secretion, slows gastric emptying, and signals fullness to the brain, all of which support postprandial glucose control and reduced caloric intake.

GLP-1 receptor activation also enhances cardiovascular function and may support renal health. Research indicates GLP-1 agonists reduce body weight by 15-22% in clinical trials, though individual responses vary based on genetics, baseline metabolic rate, and lifestyle factors.

GIP: The Emerging Metabolic Partner

Glucose-dependent insulinotropic polypeptide (GIP), formerly known as gastric inhibitory peptide, is co-released with GLP-1 after nutrient intake. GIP enhances insulin secretion in a glucose-dependent manner and influences fat tissue metabolism and energy expenditure.

Dual GLP-1/GIP agonists have emerged as a newer therapeutic approach, showing additive effects on weight loss and glycemic control. Studies suggest GLP-1/GIP combinations may produce greater weight reduction than GLP-1 monotherapy, though the magnitude of benefit varies individually.

GLP-1 and GIP Mechanisms: A Clinical Comparison

Both hormones operate through distinct yet complementary pathways. The table below outlines their primary mechanisms, tissue targets, and clinical outcomes to support informed provider discussions.

Hormone	Primary Source	Key Mechanism	Clinical Effect
GLP-1	Intestinal L-cells	Stimulates insulin, delays gastric emptying, signals satiety	Reduces appetite, improves glycemic control
GIP	Intestinal K-cells	Enhances glucose-dependent insulin, modulates lipid metabolism	Supports energy expenditure, weight reduction
GLP-1/GIP Dual	Both cell types	Synergistic signaling across both receptors	Additive metabolic and appetite effects
Individual Response	Genetic and biomarker-dependent	Receptor sensitivity, baseline insulin, adiposity	Outcomes range 10-25% body weight reduction

Genetic and Biomarker Context: Why Personalization Matters

Your response to GLP-1 or GIP-targeting therapies depends partly on genetic variation in the GLP1R and GIPR genes, as well as metabolic biomarkers like fasting insulin, C-peptide, and inflammatory markers. Individuals with certain genetic variants may experience different efficacy or side effect profiles.

Biomarkers such as insulin resistance, baseline body composition, and leptin sensitivity provide additional context for predicting treatment response. A comprehensive pre-treatment assessment helps align medication selection with your unique physiology, supporting more targeted and sustainable outcomes.

Who May Benefit: Clinical Eligibility and Safety Considerations

GLP-1 and GIP agonists are indicated for individuals with type 2 diabetes, obesity, or weight-related comorbidities, typically under physician supervision. Contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, and severe pancreatitis or gastroparesis.

Common side effects include nausea, vomiting, and constipation, which often diminish with titration. Your healthcare provider should evaluate your medical history, current medications, and metabolic profile before recommending a specific GLP-1, GIP, or dual agonist strategy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R (rs6923761) and GIPR (rs1800437) that may help provide context for your incretin hormone sensitivity and potential treatment response patterns. These genetic markers can support a more informed conversation with your provider about whether GLP-1 monotherapy, GIP-focused therapy, or a dual approach aligns with your genetic predispositions.

The genetic test also evaluates FTO (rs9939609) and MC4R (rs17782313) variants, which relate to appetite regulation and metabolic predisposition. Combined with your biomarker profile, these predispositions paint a clearer picture of your metabolic phenotype—though they do not predict exact medication response or guarantee specific weight loss outcomes.

Understanding your genetic and biomarker context can enhance provider conversations about compounded semaglutide, tirzepatide, or dual GLP-Squared formulations. When combined with lifestyle modification and regular monitoring, this personalized framework supports more intentional and sustainable weight management strategies tailored to your unique physiology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

GLP-1 and GIP in Weight Management | PlexusDx